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Abstract  
Background: The Children’s Dermatology Life Quality Index (CDLQI) is the most widely used 
instrument for measuring the impact of skin disease on quality of life (QoL) in children. 
Objective: Provide a meta-analysis of all published quality of life (QoL) scores for a range of 
childhood skin conditions. 
Methods: Studies using the Children’s Dermatology Life Quality Index (CDLQI) questionnaire to 
measure QoL in skin conditions were identified by searching Medline and Embase from January 1995 
(CDLQI creation) to December 2014. Studies were grouped according to condition and baseline 
scores were combined using meta-analysis. 
Results: 67 studies using the CDLQI met the inclusion criteria. The overall estimated CDLQI scores for 
conditions reported more than once were: atopic eczema (Point Estimate 8.5 (95% CI 7.1-9.8), 
number of studies = 38, score range = 0-29), acne (5.3 (1.9-8.5), n=5, 0-30), alopecia (3.1 (0-7.7), n=2, 
0-6), molluscum contagiosum (3.5 (0.6-6.7), n=5, 0-27), psoriasis (8.0 (3.9-12.1), n=6, 0-29), scabies 
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(9.2 (0.0-20.3), n=2, 1-26), urticaria (7.1 (0-15.4), n=2, 0-22), vitiligo (6.5 (0.7-12.2), n=2, 0-20), and 
warts (2.9 (0-5.8), n=4, 0-16). Overall, the mean effect on QoL (weighted average CDLQI score 4.6 
(95% CI 3.9 to 5.4)) for children with these conditions was small. However, many children were 
found to experience a very large impact on QoL (34% of children with atopic eczema, 10% with 
molluscum contagiosum and 1 - 5% with acne) in studies where the distributions of scores were 
provided. 
Conclusions: Most skin conditions in children have a “small” mean effect on quality of life. However, 
the range is large and a significant proportion of children with many common skin conditions will 
experience a very large effect on quality of life. 
 
Introduction 
Skin diseases can impair quality of life (QoL), sometimes causing a degree of impact similar to that of 
other chronic childhood conditions such as renal disease, cystic fibrosis and asthma (1). The 
Children’s Dermatology Life Quality Index (CDLQI) was developed to measure the impact of skin 
disease on QoL in children (2). The CDLQI has been used in over 102 studies (3) and is the most 
widely used dermatology specific instrument for measuring QoL in children (3).  Score band 
descriptors allow interpretation of the meaning of CDLQI scores (4).  
Up to now there has been no pooled summary or meta-analysis of the CDLQI scores reported in 
different skin conditions. Such a summary would allow users of the CDLQI to understand scores in 
the context of its previous use, allow comparison between different skin conditions, and utilise the 
rich data source that use of the CDLQI has created to further understand the impact of a range of 
skin conditions on QoL. Measuring the impact of skin disease on children is important for clinical, 
management, research and audit reasons, and can be helpful in guiding management decisions and 
making resource allocation decisions (1). QoL and disease severity scores can be used to inform 
clinical treatment guidelines. In the UK the National Institute for Health and Care Excellence uses 
QoL scores in the assessment of adult patients when considering biologics in the treatment of 
psoriasis (5). QoL questionnaires are mostly used in clinical research, rarely in routine clinical 
practice. However, they can be useful and are more likely to be used if the measure forms part of 
treatment planning (6) for skin conditions where the impact on QoL may often influence treatment, 
such as in severe psoriasis or atopic eczema. Therefore, a summary of the overall effect of individual 
skin conditions upon QoL may aid treatment planning.  The importance of being able to measure and 
understand CDLQI scores was emphasised by the finding that although in most children molluscum 
contagiosum causes little problems, 10% of affected children experience a very large impact on their 
QoL, suggesting that further efforts are needed to develop more effective management strategies 
for this condition(7).  
 
This study aims to conduct a meta-analysis of published QoL (CDLQI) data for a range of childhood 
skin conditions. 
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Methods 
Description of CDLQI 
The CDLQI has 10 questions asking about the impact of a skin disease on the life of the affected child 
over the last week. The topics covered include symptoms, embarrassment, friendships, clothes, 
playing, sports, school, bullying, sleep and impact of treatment. The CDLQI has been validated for 
use in children aged four to 16 years, and is available as a text or a cartoon version (2, 8). Studies 
which used either the text or cartoon version of the CDLQI were included: during the cartoon version 
validation (9) there was no significant difference in QoL scores compared to the text version, thereby 
allowing direct comparison between data collected by either format. 
CDLQI scoring algorithm 
Each response to individual questions are given a score based on standard guidelines for the CDLQI 
(2), the full CDLQI questionnaire can be accessed at http://www.cardiff.ac.uk/dermatology/quality-
of-life/childrens-dermatology-life-quality-index-cdlqi/. The scoring for each question is “Very 
much”[Score = 3], “Quite a lot”[2], “Only a little”[1], “Not at all”[0], “Blank”[0], and Q7 – “prevented 
school”[3]. The 10 individual question scores are summed to provide a total CDLQI score; the 
maximum possible score is 30, indicating maximum impact on QoL. 
CDLQI severity scoring 
Severity stratification of the CDLQI was created following the completion of an additional global 
question by 472 UK children who completed the CDLQI either in clinic or by post (4) and the bands 
were determined following the calculation of k-coefficients. The following severity bands for CDLQI 
scores were subsequently created and are used in the interpretation of QoL in this paper: 0-1 = no 
effect on QoL, 2-6 small effect, 7-12 moderate effect, 13-18 very large effect, 19-30 extremely large 
effect. 
Search Strategy 
A systematic search of bibliographical databases was carried out using a predefined search strategy 
(described below). Articles were also identified from citations within articles and from  a review (3) 
of  CDLQI use from 1995 to 2012 (3): the CDLQI was first published in 1995. 
The search terms “CDLQI” and “Children’s Dermatology Life Quality Index” were used in OVIDsp to 
search the Medline (January 1995 to December 2014) and Embase (January 1995 to December 2014) 
databases (search performed 11th February 2015). The search was restricted to articles in the English 
language and duplicates were removed (Search terms attached as supplementary materials). 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were 
adhered to in the reporting of this systematic review. 
Inclusion and exclusion criteria 
Articles were included if they were original research papers that reported QoL using the CDLQI. We 
excluded studies if data were not presented at baseline in intervention studies, if mean or median 
CDLQI scores were not presented, or if only statistical differences between CDLQI scores between 
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two time points were presented. Studies were excluded where CDLQI and DLQI scores were 
inappropriately combined as this makes it impossible to identify actual CDLQI scores(10). 
Data extraction 
All articles identified from the search were screened and data was extracted by one author (JO). 
Each article was assessed to ensure CDLQI scores were presented. Where studies met the inclusion 
criteria the following data were extracted and transferred to an electronic database; condition, 
location, setting, study design, sample size, age of subjects, CDLQI score (mean and standard 
deviation (s.d.) or median if s.d. not presented) and range of CDLQI scores (if presented). For 
intervention studies where baseline scores were given relating to separate treatment arms, both 
baseline scores were included within the review. Data concerning the clinical setting and study 
design was collected to identify any risk of bias caused by the clinical setting in which the subjects 
were seen. 
Analysis 
STATA 12 was used to explore the observed differences between mean CDLQI scores. Only articles 
which reported mean and s.d. CDLQI scores were included in the meta-analysis. Information from 
articles that reported other data is given in Supplementary Table 1. The sample-weighted average 
effect size was calculated for individual skin conditions and overall for all of the skin conditions 
included within the analysis. A random-effects model was fitted to account for the variation in 
individual study effect size(11). The I-squared (I2) index was calculated to describe the heterogeneity 
by condition and overall for all conditions included within the model, the strength of evidence for 
heterogeneity was categorised by the following; <40% may not be important, 30-60% moderate 
heterogeneity, 50-90% substantial heterogeneity, and >75% considerable heterogeneity (12).  
Results 
Literature search 
Our search identified 156 articles. After reviewing the abstracts of all 156 articles, 67 met the 
inclusion criteria (Figure 1). Within the 67 articles, CDLQI scores were given for 27 skin conditions. 
The following conditions were included: acne (number of articles=7), alopecia (n=2), atopic eczema 
(n=48), molluscum contagiosum (n=5), psoriasis (n=11), scabies (n=3), vitiligo (n=5), viral warts (n=4), 
and the following which were each reported once; buruli ulcer, congenital ichthyosis, ectodermal 
dysplasias, epidermolysis bullosa simplex, erythropoietic protoporphyria, hydroa vacciniforme, 
hypertrichosis, moles, naevi, neurofibromatosis 1, photosensitivity disorders, pigmentary 
abnormality, pityriasis rosea, scleroderma, urticaria, vascular abnormality, visible vascular and 
pigmentary conditions, and xeroderma pigmentosum (Table S1).  
Study characteristics 
Of the 67 articles, the majority described case series studies of children attending a specialist 
dermatology centre (n=45 (67.2%)). Thirteen (19.4%) were intervention studies, six (9.0%) cohort 
studies and three (4.5%) cross-sectional studies. The majority of studies described QoL in children 
recruited in the secondary care setting (n=57, 85.1%), nine recruited children from the community 
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(13.4%) and one in primary care (1.5%). Over half of the articles (n=38 (56.7%)) described children 
from Western Europe or North America.  
Most studies contained data about only one condition, however five studies, two from the UK  and 
one each from Turkey, Hong Kong and Brazil, used the CDLQI in all children attending dermatology 
outpatient clinics, covering a range of skin conditions(1, 2, 13-15). 
CDLQI scores by condition 
The meta-analysis included combined data of 7,798 children who completed CDLQI questionnaires 
for 20 skin conditions. The mean CDLQI scores of all skin conditions included within the meta-
analysis ranged between 3.9 to 5.4 (point estimate 4.6) (Figure 2), indicating that overall these 
childhood conditions have a "small" mean effect on QoL (4). However the range of scores reported 
for each condition (Figure 2) demonstrate that many subjects reported scores that indicate “very 
large" effect or “extremely large" effect on QoL, using the score band descriptors (4). The CDLQI has 
been mostly used for children with atopic eczema. The mean (s.d.) CDLQI scores were provided in 38 
studies giving a weighted average of 7.1 to 9.8 (point estimate 8.5), suggesting that atopic eczema 
has a “moderate” mean effect on QoL in children (4). This also has to be placed in context of the 
wide range of scores reported (0 to 30), with many subjects reporting scores indicating “very large 
effect” or “extremely large effect”. 
The weighted-estimated mean CDLQI scores for skin conditions reported by more than one study 
were; acne (point estimate 5.3 (95% CI 1.9 to 8.5)), alopecia (3.1 (0 to 7.7)), molluscum contagiosum 
(3.5 (0.6 to 6.7)), psoriasis (8.0 (3.9 to 12.1)), scabies (9.2 (0.0 to 20.3)), urticaria (7.1 (0 to 15.4)), 
vitiligo (6.5 (0.7 to 12.2)), and warts (2.9 (0 to 5.8)). Many of these studies were based on small 
numbers with wide confidence intervals. There was no substantial effect of heterogeneity on the 
results (‘I-squared’ – Figure 2) either for individual skin conditions or overall for all the skin 
conditions included in the analysis. 
Twenty articles (30%) described the range of CDLQI scores, most reporting a considerable range in 
QoL impairment, from between “no” effect (CDLQI score 1 or less) to some children experiencing an 
“extremely large” effect on QoL (CDLQI score 19 to 30). Figure 2 highlights the QoL impact severity 
bands (4). Six studies describing cross cultural adaptations and validation of the CDLQI were 
identified by Salek et al (3) and summarised in the Table 6 of their detailed review of CDLQI usage. 
The distribution of QoL scores by condition was described in six studies (Table 1). Only the studies 
reporting molluscum contagiosum and atopic eczema used the exact validated score banding 
descriptors (4).  
Discussion 
Overall the skin conditions included within this meta-analysis were found to have a “small” mean 
effect on QoL.  However this overall conclusion gives a misleading view of the reality of the impact of 
skin diseases on QoL from the perspective of the health care services The range of CDLQI scores 
reported for most conditions (in those 30% of studies which report them) together with stratification 
of severity of effect in a limited number of studies suggests that a considerable number of subjects 
may experience major impact, implying they could require urgent appropriate treatment. Given the 
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high prevalence of skin disease, even if only say 10% of children have such high scores, they still 
constitute a critically important cohort of patients potentially needing high resource use treatments.  
There is most information for the highly prevalent condition of atopic eczema, with an overall mean 
“moderate” effect on QoL in children. One study provided a detailed description of QoL impact for 
children with atopic eczema, 34% of children experienced a “very large” or “extremely large” impact 
on their QoL (16).  
Skin conditions can impact on a child’s QoL in many ways and for those with atopic eczema the most 
predominate problems are scratching, sleep disturbance, mood change, problems at meal-time, 
dressing and bathing, playing and treatment difficulties (17). Previous research has shown atopic 
eczema having a great impact on QoL compared to other skin conditions, with only scabies and 
psoriasis having a greater impact (17). Most studies measuring impact on QoL often collect data over 
a fairly short time period and do not take into account the time course or curability of different 
conditions. For example, scabies might have a large effect on QoL at the time of completing the 
questionnaire but this may only be over a short time period as it is curable.  Both of the two studies 
that measured QoL in children with scabies included within our data (2, 13) reported a high impact 
on QoL, however both had small sample sizes (n=6, 9) with wide confidence intervals. For psoriasis 
there were five studies with a wide range of CDLQI scores, leading to wide confidence intervals 
within the meta-analysis and describing a small to moderate average effect on QoL. Many other 
conditions had wide confidence intervals which suggest the impact on QoL may be a moderate or 
substantial effect within the meta-analysis and have a greater impact on QoL than atopic eczema.  
Although a third of the articles provided the range of CDLQI scores, only six studies gave a detailed 
description of the proportion of children within CDLQI score descriptor bands. The most detailed 
description was provided for a cohort of children with molluscum contagiosum (7).  
The point estimate of the centre of the CDLQI score distribution is important as it provides detail of 
the average severity and potential cost of a condition. However it does not convey the distribution 
of scores or allow one to determine how many children may need to be treated in specialist centres 
or receive more active/complex therapies. These therapies can be costly and of great significance to 
both primary and secondary care due to them requiring more frequent consultations and potentially 
more expensive management.  
A comprehensive review (3) of all publications reporting use of the CDLQI has revealed strengths and 
weaknesses concerning its validation. There is evidence of high internal consistency, test–retest 
reliability, responsiveness to change, and significant correlation with other subjective and objective 
measures. However Rasch analysis has not been carried out and more information is needed 
concerning minimal clinically important difference; these are areas requiring further study. One 
study (13) identified that Factor loading scores of a two-factor solution of CDLQI items ranged 
between 0_07–0_74 for factor 1 and 0_09–0_83 for factor 2: further work is needed to assess the 
question of unidimensionality of this instrument. 
The main limitations of this meta-analysis are that data from studies using various designs and 
different populations have been combined and the data may not be generalisable to other settings. 
Typically dermatologists are referred the most severe and complicated cases from primary care, and 
so the CDLQI scores reported from secondary care may be higher than typical cases existing in the 
community; however in conditions in which data is available from both secondary care and 
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community settings for adults using the DLQI, the QoL scores were comparable (18).  There is also 
the possibility that a greater impact upon QoL may be a determinant of referral to secondary care, 
along with the severity of disease, parental QoL, and impact upon daily activities, all of which may 
interact with the child’s QoL. The CDLQI has not been formally validated as a QoL measurement 
questionnaire in the primary care or community setting, however where the Dermatology Life 
Quality Index (DLQI) was used to assess the impact of skin conditions on QoL in adults, the scores in 
primary care were comparable to that of patients seen in secondary care(18).  The spectrum of QoL 
impact of skin disease experienced by children seen by dermatologists may differ depending on 
whether patients are seen directly by dermatologists or whether they are initially seen by primary 
care “gatekeepers”.  A high CDLQI score may be helpful information to primary care physicians, 
prompting appropriate urgent referral to secondary care or informing management decisions.  
A limitation of this systematic review is that only one author reviewed the papers and conducted 
data extraction for the search. It is however best practice for both the systematic search results and 
data extraction to be reviewed independently by at least two reviewers to minimize the chance of 
missing relevant information. The search could have been influenced by the bias inherent in having 
only one reviewer, and this may reduce the validity of our results. To provide transparency in the 
search methods, and conforming to the PRISMA statement (19), the method of study selection 
including search strategy, process for selecting studies, and method of data extraction have been 
described explicitly in the Methods section above and consistently adhered to.  
There are many methods to measure the impact of a skin condition on QoL: the CDLQI is an 
instrument which can be used across many different skin conditions in affected children. In general, 
generic instruments are not as sensitive, responsive or relevant to individual patients as disease 
specific instruments(20). However for most skin conditions in children no disease specific measures 
exist, and from the practical clinical perspective it is easier for clinicians to use and become familiar 
with the meaning of scores of a single dermatology-specific instrument. The CDLQI has been used in 
over 100 published studies, providing a rich and wide data source allowing comparison of QoL 
impact for a combined sample of 7,798 children with 20 skin conditions to be presented within one 
meta-analysis. 
We excluded studies based upon language (search limited to English language only).  This aspect of 
the search strategy is a limitation of the study as potentially important findings may have been 
excluded.  However excluding research published in languages other than English has been found to 
have little effect on summary effect estimates(21). 
The CDLQI is a useful instrument which can measure the impact of skin disease on QoL in 
populations of children whether or not other non-skin conditions are present, and allows 
comparisons between children with a wide range of different skin conditions(2). The results of this 
study provide overall CDLQI scores for individual conditions that may assist treatment planning and 
the interpretation of scores in the clinical setting and in future studies. 
What's already known about this topic?
• Skin conditions can impact upon a child’s quality of life. 
• Quality of life measures that inform treatment planning are more likely to be used in 
clinical practice. 
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Tables 
Table 1: Conditions describing proportion of children and severity of QoL impact 
Condition QoL impact severity bandings (4) 
None or small Moderate  Large or extremely large 
Acne (22) 67.0% 28.0% 5.0% 
Acne  (23) 90.0% 8.1% 1.6% 
Atopic eczema (16) 28.0% 38.0% 34.0% 
Erythropoietic protoporphyria (24) 20.0% 80.0% 
Molluscum contagiosum (7) 71.8% 17.3% 10.9% 
Vitiligo (25) 88.0% 5.0% 7.0% 
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Figure Legends 
Figure 1: Flow chart of study selection process 
 
 
 
 
 
 
 
 
 
Figure 2: Comparison of mean CDLQI scores by skin condition 
Note: CDLQI scores reported in 67 studies. Each horizontal line represents the range of scores with 
the mean indicated. The solid vertical line represents the overall mean.  The dotted vertical lines 
divide the score band descriptors(4): 0-1 = no effect on QoL, 2-6 small effect, 7-12 moderate effect, 
13-18 very large effect, 19-30 extremely large effect. 
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